CRSP icon

CRISPR Therapeutics

416 hedge funds and large institutions have $3.07B invested in CRISPR Therapeutics in 2023 Q2 according to their latest regulatory filings, with 65 funds opening new positions, 94 increasing their positions, 136 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

more first-time investments, than exits

New positions opened: | Existing positions closed:

more funds holding in top 10

Funds holding in top 10:

more call options, than puts

Call options by funds: $ | Put options by funds: $

more capital invested

Capital invested by funds: $ → $

9% more funds holding

Funds holding: 380416 (+36)

2.1% less ownership

Funds ownership: 71.47%69.38% (-2.1%)

31% less repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 136

Holders
416
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$142M
Puts
$112M
Net Calls
Net Calls Change

Top Sellers

1 -$36.6M
2 -$24.7M
3 -$24.6M
4
State Street
State Street
Massachusetts
-$19.9M
5
AC
Armistice Capital
New York
-$18.2M
Name Holding Trade Value Shares
Change
Change in
Stake
76
$3.62M
77
$3.58M
78
$3.49M
79
$3.42M
80
$3.25M
81
$3.2M
82
$3.2M
83
$3.13M
84
$2.97M
85
$2.91M
86
$2.81M
87
$2.81M
88
$2.74M
89
$2.38M
90
$2.36M
91
$2.31M
92
$2.28M
93
$2.25M
94
$2.13M
95
$2.05M
96
$2.03M
97
$1.99M
98
$1.95M
99
$1.93M
100
$1.9M